Elanco Animal Health Incorporated [NYSE: ELAN] loss -7.03% on the last trading session, reaching $30.29 price per share at the time. The company report on November 6, 2020 that Elanco Animal Health Reports Third Quarter 2020 Results.
Revenue in the third quarter was $889.6 million, comprised of $694.0 million from the legacy Elanco portfolio and $195.6 million from the legacy Bayer Animal Health portfolio.
Gross margin was 50.3% on a reported basis and 54.2% on an adjusted basis, benefiting from the addition of the Bayer Animal Health portfolio as well as continued productivity improvements.
Elanco Animal Health Incorporated represents 413.20 million in outstanding shares, while the company has a total market value of $14.52 billion with the latest information. ELAN stock price has been found in the range of $26.72 to $31.37.
If compared to the average trading volume of 4.01M shares, ELAN reached a trading volume of 10660165 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Elanco Animal Health Incorporated [ELAN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ELAN shares is $30.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ELAN stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Elanco Animal Health Incorporated shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 20, 2020. While these analysts kept the previous recommendation, Credit Suisse raised their target price to Neutral. The new note on the price target was released on August 13, 2020, representing the official price target for Elanco Animal Health Incorporated stock. Previously, the target price had yet another raise to $26.50, while Goldman analysts kept a Buy rating on ELAN stock.
The Average True Range (ATR) for Elanco Animal Health Incorporated is set at 1.51, with the Price to Sales ratio for ELAN stock in the period of the last 12 months amounting to 5.18. The Price to Book ratio for the last quarter was 1.88, with the Price to Cash per share for the same quarter was set at 2.90.
Trading performance analysis for ELAN stock
Elanco Animal Health Incorporated [ELAN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.32. With this latest performance, ELAN shares dropped by -5.73% in over the last four-week period, additionally plugging by 45.84% over the last 6 months – not to mention a rise of 12.52% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ELAN stock in for the last two-week period is set at 47.68, with the RSI for the last a single of trading hit 43.50, and the three-weeks RSI is set at 50.82 for Elanco Animal Health Incorporated [ELAN]. The present Moving Average for the last 50 days of trading for this stock 29.46, while it was recorded at 31.53 for the last single week of trading, and 25.37 for the last 200 days.
Elanco Animal Health Incorporated [ELAN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Elanco Animal Health Incorporated [ELAN] shares currently have an operating margin of +12.05 and a Gross Margin at +45.60. Elanco Animal Health Incorporated’s Net Margin is presently recorded at +2.21.
Return on Total Capital for ELAN is now 4.73, given the latest momentum, and Return on Invested Capital for the company is 0.87. Return on Equity for this stock inclined to 1.26, with Return on Assets sitting at 0.76. When it comes to the capital structure of this company, Elanco Animal Health Incorporated [ELAN] has a Total Debt to Total Equity ratio set at 44.00. Additionally, ELAN Total Debt to Total Capital is recorded at 30.55, with Total Debt to Total Assets ending up at 27.16. Long-Term Debt to Equity for the company is recorded at 43.13, with the Long-Term Debt to Total Capital now at 29.95.
Reflecting on the efficiency of the workforce at the company, Elanco Animal Health Incorporated [ELAN] managed to generate an average of $11,788 per employee. Receivables Turnover for the company is 3.84 with a Total Asset Turnover recorded at a value of 0.34.Elanco Animal Health Incorporated’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.50 and a Current Ratio set at 3.80.
Elanco Animal Health Incorporated [ELAN]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Elanco Animal Health Incorporated posted 0.3/share EPS, while the average EPS was predicted by analysts to be reported at 0.26/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 15.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ELAN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Elanco Animal Health Incorporated go to 8.28%.
An analysis of insider ownership at Elanco Animal Health Incorporated [ELAN]
There are presently around $11,897 million, or 87.10% of ELAN stock, in the hands of institutional investors. The top three institutional holders of ELAN stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 45,879,978, which is approximately -1.681% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 37,125,269 shares of the stock with an approximate value of $1.12 billion in ELAN stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $1.04 billion in ELAN stock with ownership of nearly -0.608% of the company’s market capitalization.
Positions in Elanco Animal Health Incorporated stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 198 institutional holders increased their position in Elanco Animal Health Incorporated [NYSE:ELAN] by around 52,787,291 shares. Additionally, 185 investors decreased positions by around 65,816,874 shares, while 51 investors held positions by with 274,151,689 shares. The mentioned changes placed institutional holdings at 392,755,854 shares, according to the latest SEC report filing. ELAN stock had 74 new institutional investments in for a total of 6,928,551 shares, while 67 institutional investors sold positions of 9,771,354 shares during the same period.